Articles for category: Most Popular

Russ Cohen

Most Popular

Amazon Seeks to Revolutionize Streaming Advertising Amazon Seeks to Revolutionize Streaming Advertising

Amazon.Com Inc’s introduction of ads on Prime Video will likely impact the crowded U.S. streaming market significantly. As the third-largest digital ad seller globally, Amazon’s $12 billion ad revenue in the third quarter marks a 26% increase from the previous year. Their vast customer data offers a unique edge in targeted advertising. Analysts see $6.6 ...

Russ Cohen

Most Popular

Understanding the Recent Legal Setback for Genmab and Its Implications for Investors Understanding the Recent Legal Setback for Genmab and Its Implications for Investors

Monday brought significant legal news for Genmab A/S (NASDAQ: GMAB) as an appeal arbitrator dismissed the biotech company’s bid for additional milestone and royalty payments related to Darzalex (daratumumab). In an SEC filing, Genmab revealed that the appeal arbitrator in its second arbitration under the license agreement with Janssen Biotech Inc, Johnson & Johnson’s (NYSE: ...

Russ Cohen

Most Popular

PACCAR Quarterly Earnings Overview

PACCAR PCAR, a trucking giant, will unveil its fourth-quarter 2023 results tomorrow, before the stock market opens. Analysts predict earnings per share of $2.20 and revenues of $8.18 billion for the quarter. The consensus estimate for PACCAR’s earnings per share has risen by 3 cents in the past seven days, indicating a potential 25% growth ...

Russ Cohen

Most Popular

Alibaba (BABA) Stock: Evaluating Wall Street Analyst Recommendations Alibaba (BABA) Stock: Evaluating Wall Street Analyst Recommendations

Investors frequently turn to analyst recommendations when considering stock transactions, but how much weight should one give these endorsements? Let’s explore Wall Street’s take on Alibaba (BABA) and delve into the reliability of brokerage endorsements as well as strategies for leveraging them. Analyst Recommendations for Alibaba Alibaba currently boasts an average brokerage recommendation (ABR) of ...

Russ Cohen

Most Popular

HW Wainwright Downgrades Aclaris Therapeutics HW Wainwright Downgrades Aclaris Therapeutics After Underwhelming Study Data

ATU Images/The Image Bank via Getty Images HC Wainwright, an investment bank, has recently downgraded Aclaris Therapeutics (NASDAQ:ACRS) to a neutral rating. This decision comes in response to underwhelming data from a Phase 2 study involving the company’s drug ATI-1777, which was being evaluated for the treatment of atopic dermatitis, or AD. According to the ...

Russ Cohen

Most Popular

First Wave BioPharma: Leading the Charge in Celiac Therapy Innovation

James Sapirstein, Chairman, President & CEO of First Wave BioPharma, Inc. FWBI recently shared insights on Benzinga’s All-Access. First Wave BioPharma is dedicated to pioneering non-systemic therapies for gastrointestinal (GI) diseases. The company is pursuing research on numerous revolutionary therapies for GI diseases. You can watch the full interview here. Featured photo by Hans Reniers ...